BSPGHAN / UCLAN Systematic review fellowship 2022-3

We are delighted to announce the launch of this fellowship opportunity. This is a joint opportunity brought to you by the BSPGHAN research committee and Professor Morris Gordon, Director of the Biomedical Evidence synthesis and Translation to practice (BEST) unit at the University of Central Lancashire (UCLAN). The unit houses the Cochrane Gut UK review group, managing the Paediatric IBD and functional bowel disease portfolios. The team have produced 35 systematic reviews, including 20 Cochrane reviews, in the last 3 years.

One successful candidate will be offered a funded secondment from 1st August 2022 for 12 months of 0.1-0.2 FTE. During this time, they will be offered bespoke training in systematic review techniques needed for Cochrane and non-Cochrane reviews. They will join the team for between one and three reviews, with a specific focus on reviews of functional constipation in childhood. These are being produced after requests from the Dutch guidelines team and the NASPGHAN motility committee, with the outputs therefore likely being used to inform these key guidelines.

This is open to all members of BSPGHAN, regardless of their seniority or professional group, and including allied health professionals. No specific skills, with the team currently working with authors at all stages of training and levels of experience. There will be no changes to or interference with clinical activities as per RCPCH portfolio for any successful BSPGHAN trainees, who will receive the support and flexibility required to undertake this fellowship in addition to their core activities.

Virtual working can be fully accommodated. The specific FTE commitment will depend on the individual pay grade of the successful candidate. Once appointed, an agreement between the candidates lead employer will be completed to allow a secondment during the fellowship, with backfill of pay from UCLAN to the lead employer (ensuring there is no change in pay terms or conditions for the candidate and rapid organisation of the role). The role will be subject to agreement by the lead employer for the secondment terms.

We would invite candidates to return the application form by 27th May 2022 to

Informal enquiries can also be made to Professor Gordon by email

or Marco Gasparetto

Surveying National Prevalence, Investigation and Management of Congenital Sucrase-Isomaltase Deficiency (CSID)

Currently there is no clinical standard for investigation / management of congenital sucrase-isomaltase deficiency (CSID). Dr Sam Huthart, Dr Zamvar, Dr Sims and Dr Kontaki from Leeds Teaching Hospitals Trust have put together a google form with the aim of surveying national prevalence, investigation and management of CSID to obtain epidemiological data and establish best-practice. 

To all paediatric gastroenterologists nationwide please help the Leeds team to achieve these outcomes by completing the following survey: Surveying National Prevalence, Investigation and Management of Congenital Sucrase-Isomaltase Deficiency (CSID) – Google Forms

BSPGHAN /RCPCH audit launched 16th December 2021

Dear members

I would like to personally thank the PGHAN Audit Steering Group, co chaired by John Fell and Ed Gaynor, Calvin Down from the RCPCH and all colleagues across the UK who have put time and effort into collecting and submitting information for the audit. This work continued to completion during the incredibly challenging circumstances of the COVID-19 pandemic.

This report, published jointly by The British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) and the RCPCH, highlights the main findings and recommendations identified through an audit of the provision of paediatric gastroenterology, hepatology and nutrition services for infants, children and young people with a wide range of conditions across the UK. Its recommendations offer healthcare professionals and providers expert guidance to drive improvement where needed.

The News page is here :

Download your copy of The PGHAN/Audit report

Download Summaryof the PGHAN/ Audit report

Also see tweets

Sue Protheroe
BSPGHAN President 2019 – 2022

BSPGHAN DISTINGUISHED SERVICE AWARD – call for nominations now closed

BSPGHAN Council thank BSPGHAN members for nominations for the 2021 BSPGHAN Distinguished Service Award. The decision on who will receive the award will be announced at the BSPGHAN Gala Dinner on Thursday 27th January 2022

A call for nominations will be advertised on the BSPGHAN website  in September  each year.  

Please download the full details for eligibility, standards, criteria and selection process.

*A Full or Associate member of BSPGHAN for at least 5 years at the time of nomination.  

Please remember that Honorary Membership may also be conferred by the Society, at the recommendation of Council, upon distinguished colleagues who have made an outstanding contribution to paediatric gastroenterology, whether they be members of the Society or not. Upon retirement, Full Members may apply in writing to the Convenor to become Honorary Members. Honorary Members are not be required to pay the annual subscription fee and do not have voting rights at the Annual General Meeting nor at Special Meetings. 

Best wishes

Sue Protheroe 

President of BSPGHAN 18/8/21 

Updated JCVI Guidance –  Covid vaccination of children and young people aged 12- 17 years

Updated JCVI Guidance – Covid vaccination of children and young people aged 12- 17 years

Dear members

Please see updated Guidance from the JCVI

in addition to previous advice

At this time,

  • the Pfizer-BioNTech BNT162b2 vaccine is the only vaccine authorised for persons aged 12 to 17 years in the UK
  • JCVI advises that all 16 to 17-year-olds should be offered a first dose of Pfizer-BNT162b2 vaccine. 
  • Persons aged 12 to 15 years with specific underlying health conditions that put them at risk of severe COVID-19, should be offered 2 doses of Pfizer-BNT162b2 vaccine with an interval of 8 weeks between doses.

This currently includes children with severe neuro-disabilities, Down’s Syndrome, underlying conditions resulting in immunosuppression, profound and multiple learning disabilities (PMLD), severe learning disabilities or who are on the learning disability register. Details regarding additional person-groups with underlying health conditions to be offered vaccination will be provided as updates in the Green Book.

Children and young people aged 12 years and over who are household contacts of persons (adults or children) who are immunosuppressed should be offered 2 doses of Pfizer-BNT162b2 vaccine.

The rollout of Covid vaccination in England will be led through primary care. The letter notes: “We recognise that not all eligible 12-15 year olds may be identified through the GP record. Therefore, any approach by parents of children at increased risk should be considered and clinical judgement used around eligibility in line with JCVI advice. In addition, trusts may refer 12-15 year olds for a COVID-19 vaccination if they consider them to be eligible”

Letter to primary care –

FAQs on Vaccination delivery operations

Best wishes


Dr S Protheroe
BSPGHAN President

Contact Us  l  Privacy Policy  l  Members Login  

© 2021 British Society of Paediatric Gastroenterology, Hepatology and Nutrition  l Charity Number 299294 l VAT registration number 323665308
Website design and development by KYL.